Seattle Institute for Biomedical and Clinical Research
sibcr.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
48
Active
9
Phase 3
4
Total enrollment
13,297
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| testosterone 1.62% gel | — | — | — | — | — | 1 | |
| Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED] | — | — | — | — | — | 1 |
Next readouts
- 2026-11
- 2027-01-30
Top conditions
- Stress Disorders, Post-Traumatic4
- Posttraumatic Stress Disorder3
- Obesity3
- Alcoholism3
- Impaired Glucose Tolerance2
- Prediabetes2
- Impaired Fasting Glucose2
- Irritable Bowel Syndrome2
Frequently asked questions about Seattle Institute for Biomedical and Clinical Research
- How many clinical trials does Seattle Institute for Biomedical and Clinical Research have on ClinicalTrials.gov?
- Seattle Institute for Biomedical and Clinical Research is listed as the lead sponsor on 48 clinical trials in ClinicalTrials.gov, 9 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Seattle Institute for Biomedical and Clinical Research's trials are in Phase 3?
- 4 of Seattle Institute for Biomedical and Clinical Research's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Seattle Institute for Biomedical and Clinical Research focus on?
- Seattle Institute for Biomedical and Clinical Research's most-studied conditions on ClinicalTrials.gov are Stress Disorders, Post-Traumatic, Posttraumatic Stress Disorder, Obesity, Alcoholism, Impaired Glucose Tolerance.
- When are Seattle Institute for Biomedical and Clinical Research's next clinical trial readouts?
- Seattle Institute for Biomedical and Clinical Research has 2 upcoming primary-completion readouts tracked here; the soonest is “Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency”, expected around 2026-11.